Decisions on statin therapy by patients' opinions about survival gains: cross sectional survey of general practitioners

BMC Fam Pract. 2015 Jul 3:16:79. doi: 10.1186/s12875-015-0288-8.


Background: Guidelines for primary prevention of cardiovascular disease provide little guidance on how patients' preferences should be taken into account. We wanted to explore whether general practitioners (GPs) are sensitive to patient preferences regarding survival gains from statin therapy.

Methods: In a cross sectional, online survey 3,270 Norwegian GPs were presented with a 55 year old patient with an unfavourable cardiovascular risk profile. He expressed preferences for statin therapy by indicating a minimum survival gain that would be considered a substantial benefit. This survival gain varied across six versions of the vignette: 8, 4 and 2 years, and 12, 6 and 3 months, respectively. Participants were randomly allocated to one version only. We asked whether the GPs would recommend the patient to take a statin. Subsequently we asked the GPs to estimate the average survival gain of life long simvastatin therapy for patients with a similar risk profile.

Results: We received 1,296 responses (40 %). Across levels of survival gains (8 years to 3 months) the proportion of GPs recommending statin therapy did not vary significantly (OR per level 1.07, 95 % CI 0.99 to 1.16). The GP's own estimate of survival gain was a statistically significant predictor of recommending therapy (OR per year adjusted for the GPs' age, sex, speciality attainment and number of patients listed 3.07, CI 2.55 to 3.69).

Conclusion: GPs were insensitive to patient preferences regarding survival gain when recommending statin therapy. The GPs' recommendations were strongly associated with their own estimates of survival gain.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Attitude of Health Personnel*
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / mortality
  • Clinical Decision-Making / methods*
  • Cross-Sectional Studies
  • Female
  • General Practitioners / psychology*
  • General Practitioners / statistics & numerical data
  • Health Care Surveys
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Logistic Models
  • Male
  • Middle Aged
  • Norway
  • Patient Participation
  • Patient Preference*
  • Practice Patterns, Physicians' / statistics & numerical data*


  • Hydroxymethylglutaryl-CoA Reductase Inhibitors